Genialis™ krasID

First-in-class patient classifier predicts response and stratifies clinical benefit of KRAS inhibition

Genialis krasID is designed to predict and monitor drug response from the simplest preclinical models to intent-to-treat real world patient cohorts

We welcome you to explore & evaluate the biomarker.
Schedule a free consultation with our experts to begin!

Make the best informed translational and clinical decisions for your drug program

Genialis™ krasID predicts response and benefit of KRAS inhibition at any stage of the drug lifecycle

Genialis krasID covers the entire lifecycle of drug development

  • Preclinical studies
    Identify superior drug candidates on preclinical models versus the competitive field

  • Clinical development
    Classify patients based on predicted drug response & define cohorts for various indications

  • Real world care
    Predict clinical benefit & monitor patient response to maximize time on drug and inform combinations

Genialis™ krasID predicts clinical benefit consistent with real world & clinical findings

  • Real World Data
    Patients stratified as krasID-HIGH vs. krasID-LOW demonstrate dramatically different time on treatment

  • Clinical Trial
    Cohort characteristics and response results align closely with CodeBreaK100/200 clinical trial observations, demonstrating accuracy in forecasting outcomes in clinical trial settings.

  • Time on Treatment
    krasID-High patients stayed on sotorasib nearly 50% longer than G12C-selected patients and ~2.0x longer than krasID-LOW patients

KM plot of predicted benefit to sotorasib in a NSCLC RWE cohort

Genialis™ krasID outperforms current Standard of Care Biomarkers, which are limited to mutational status

Historical Approach

  • Limited to presence or absence of DNA mutation

  • Perhaps necessary, but utterly insufficient to predict efficacy (mutation selected ORR ~ 30-40%)

  • Cannot inform time on treatment or combination strategies

Genialis™ krasID Advantage

  • Integrates signal from KRAS biology with surrounding tumor milieu using RNA-seq & ML

  • Predicts response with >94% accuracy in preclinical models and >80% accuracy in real world patients

  • Stratifies patients based on time on treatment/survival

  • Reads out actionable changes to other therapeutically relevant biologies

The current KRASi development landscape is crowded; Next-generation biomarkers will provide differentiation

Two drugs currently on market

FDA approved KRAS G12C Inhibitors

Competition to get to market

>50 companies competing across ~7 different solid tumor indications 2

Competition to get to market, >50 companies competing across ~7 different solid tumor indications

1 Tian H, Yang Z, He J. Adagrasib: A landmark in the KRASG12C-mutated NSCLC. MedComm (2020). 2022 Nov 25;3(4):e190. doi: 10.1002/mco2.190. PMID: 36448054; PMCID: PMC9697582.
2 Biocentury Inc. “KRAS Pipeline” (2024)

More than 50 companies are competing to bring KRAS drugs to market, with the ‘best-in-class’ distinction yet to be claimed.

Gain the edge for clinical trial success and market share by stratifying your patient population with 80% predictability.

We welcome you to explore & evaluate Genialis™ krasID.
Schedule a free consultation with our experts to begin!